-
Imprimis Pharma's (IMMY) CEO Publishes Drug Pricing Monograph
-
Following Congressional Hearing Investigating Mylan and Epi-Pen, Imprimis Pharmaceuticals Founder and CEO Publishes Drug Pricing Monograph
-
Imprimis Pharmaceuticals to Make a Lower Cost Compounded and Customizable Alternative to Thiola®
-
Express Scripts (ESRX), Imprimis Pharma (IMMY) to Partner on Low-Cost Alternative to Turing's Daraprim
-
Express Scripts Champions $1 per Pill Access to an Alternative for Daraprim
-
Imprimis Pharma (IMMY) Launches Customizable Compounded Formulation of Pyrimethamine + Leucovorin
-
Imprimis Pharmaceuticals to Make Compounded and Customizable Formulation of Pyrimethamine and Leucovorin Available for Physicians to Prescribe for their Patients as an Alternative to Daraprim®

